Three cases of palmoplantar pustulosis successfully treated with apremilast

Successful treatment of pustulotic arthro-osteitis with apremilast: a case report with follow-up MRI

“…Severe cases of PPP are treated with oral retinoid, cyclosporine, methotrexate, and colchicine [3]. In 2019, Eto et al reported three cases of PPP successfully treated with apremilast, which is a PDE-4 inhibitor broadly used for the treatment of psoriasis [4]. Similar to the previous report, in the present case, apremilast was found to improve palmoplantar exanthema and nail psoriasis.…”

Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments

“…Four papers have published promising data on apremilast in the treatment of PPP [110][111][112][113]. Two retrospective studies (with a total of 12 subjects) investigated apremilast in combination with ustekinumab, methotrexate, or ixekizumab and showed good clinical response [110,113].…”

“…Two retrospective studies (with a total of 12 subjects) investigated apremilast in combination with ustekinumab, methotrexate, or ixekizumab and showed good clinical response [110,113]. Another four cases of PPP successfully treated with apremilast in monotherapy have also been published [111,112]. Prospective studies in more patients are needed to confirm these observations.…”

Effects of apremilast on pustulotic arthro‐osteitis in a real‐world setting: Report of five cases

“…Recently, Eto et al (2019) reported that apremilast was effective for PPP in three patients, in one of whom apremilast was also effective for PAO. By contrast, in our cases, the effects of apremilast were not parallel in the skin and joint manifestations.…”

“…Apremilast blocks phosphodiesterase-4, which regulates immune and inflammatory process through modification of the levels of intracellular cyclic adenosine monophosphate, protein kinase A, and various inflammatory cytokine production. To date, only a few cases have been reported on apremilast therapy for PAO or SAPHO syndrome (Adamo et al, 2018;Eto, Nakao, & Furue, 2019;Takama et al, 2019).…”